Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease.

Tamm, M; Gratwohl, Aloïs; Thewis, André; Perruchoud, André P.; Tyndall, Alan

doi:10.1136/ard.55.10.779

Cited by 58 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…None of the approximately 30 patients reported in detail in publications died. [17][18][19][20][21][22][23][24] In contrast, nine patients of the 74 in this phase I/II pilot study have died, two even before the transplant. Mortality during mobilisation is rarely reported.…”

Section: Discussionmentioning

confidence: 88%

Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality

Tyndall

Fassas²,

Passweg³

et al. 1999

Bone Marrow Transplant

Self Cite

151

View full text Add to dashboard Cite

Summary:This ongoing multicentre prospective phase I/II trial enrolled 74 consecutive patients from 22 centres worldwide with severe autoimmune disease, 35 with rheumatological disorders, 31 with neurological, five with haematological and three with vasculitides. They were treated with autologous peripheral blood or bone marrow transplants according to predetermined criteria. Two patients died after mobilisation before transplant. Seventy-two patients were given 73 transplants, seven bone marrow, and 66 mobilised peripheral blood stem cell transplants. The graft was manipulated to remove T and/or B cells in 43 cases. All 73 transplants engrafted. Five patients died of transplant-related complications: two from bleeding, three from infections. Two patients died of progressive disease. The transplant-related mortality at 1 year of 9% (1-17%; 95% CI) is comparable to the transplant-related mortality of 6% (3-9%; 95% CI) in patients transplanted during the same period in Europe for non-Hodgkin's lymphoma in sensitive relapse (P = 0.39). Sixty patients are evaluable for response, 40 patients (65%) showed some improvement in their disease. Haematopoietic stem cell transplants are feasible for patients with severe refractory autoimmune disease. Transplant-related mortality is comparable to results in patients with non-Hodgkin's lymphoma in responsive relapse. Two-thirds of the patients show at least some response. These preliminary data are promising. Although associated with considerable risk, randomised trials comparing autologous stem cell transplants to conventional therapy are warranted.

show abstract

Section: Discussionmentioning

confidence: 88%

Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality

Tyndall

Fassas²,

Passweg³

et al. 1999

Bone Marrow Transplant

Self Cite

151

View full text Add to dashboard Cite

show abstract

“…The idea arose from coincidental case reportshematopoietic stem cell transplant (HSCT) given for the treatment of malignancy with coexisting AD (2)-and was corroborated by animal model data (3). The first patients receiving an HSCT for an AD had systemic sclerosis (SSc) (4,5) and responded satisfactorily with durable remissions.…”

Section: Hematopoietic Stem Cell Transplantation In Auto Immune Diseasementioning

confidence: 99%

Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases

Tyndall

2012

Pediatr Res

View full text Add to dashboard Cite

“…In terms of such serious prognosis, SSc was one of the first reported cases of autoimmune disease where HCT was applied [57]. Since then, most of numerous small case series and phase I/II studies and three randomized trials demonstrated encouraging data.…”

Section: Hct For Systemic Sclerosismentioning

confidence: 96%

“…The first report of HCT for autoimmune disease treatment as a primary indication was published in 1996 [57]. In the late 1990s of 20th century, a Joint Committee of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT), joined by several North American and Australian centers, referred to as the International Autoimmune Disease Stem Cell Project, initiated a phase I/II study to assess feasibility, mortality, and preliminary response for this treatment model, performed for isolated autoimmune disease [34][35][36].…”

Section: Progress In Transplantation For Autoimmune Diseasesmentioning

confidence: 99%

Hematopoietic Cell Transplantation for Autoimmune Diseases: A Review of History, Current State, and Future Issues

Resnick¹,

Metodiev²,

Lazarova³

2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

Autoimmune diseases are characterized by recurrent attacks and remissions, but as a rule they progress and eventually cause a severe disability and death. The present chapter contains general characteristics of autoimmune disease pathogenesis, ways to cause immune tolerance by hematopoietic cell transplantation (HCT), clinical aspects of the treatment for established autoimmune diseases with a special attention to multiple sclerosis (MS) and systemic sclerosis (SSc). A profound analysis of authors' point of view and of the available literature has been performed. The promising results allows to consider HCT as a relevant treatment option for a certain autoimmune diseases.

show abstract

Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease.

Cited by 58 publications

References 8 publications

Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality

Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality

Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases

Hematopoietic Cell Transplantation for Autoimmune Diseases: A Review of History, Current State, and Future Issues

Contact Info

Product

Resources

About